SCHEMBL2107333

SCHEMBL2107333

COc1ccc2[nH]c(=O)[nH]c2c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.66
HPGD P15428 4/20 0.66
GFER P55789 2/20 0.66
ALDH1A1 P00352 5/20 0.55
KDM4E B2RXH2 4/20 0.55
MAPT P10636 3/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
TSHR P16473 1/20 0.55
TP53 P04637 1/20 0.55
POLB P06746 1/20 0.55
PDE3B Q13370 3/20 0.55
PDE3A Q14432 3/20 0.55
DRD2 P14416 1/20 0.51
ESR2 Q92731 1/20 0.50
ABCG2 Q9UNQ0 1/20 0.50
AXL P30530 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30076444 1.00 HSD17B10 (0.66) HSD17B10HPGDGFERALDH1A1KDM4E
SCHEMBL5955310 0.89 HPGD (0.53) HSD17B10HPGDGFERALDH1A1KDM4E
SCHEMBL12677211 0.88 HSD17B10 (0.66) HSD17B10HPGDGFERALDH1A1KDM4E
Propionic Acid SCHEMBL8125881 0.87 HPGD (0.51) HSD17B10HPGDGFERALDH1A1KDM4E
SCHEMBL3124589 0.81 ALDH1A1 (0.63) HSD17B10HPGDGFERALDH1A1KDM4E
SCHEMBL7028805 0.81 KDM4E (0.60) HSD17B10HPGDGFERALDH1A1KDM4E
SCHEMBL31275105 0.81 KDM4E (0.60) HSD17B10HPGDGFERALDH1A1KDM4E
SCHEMBL5788217 0.81 ALDH1A1 (0.56) ALDH1A1PDE3BPDE3ASMN1; SMN2
SCHEMBL20777399 0.81 GAA (0.51) HSD17B10HPGDGFERALDH1A1MEN1
SCHEMBL30832803 0.81 GAA (0.51) HSD17B10HPGDGFERALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107188771-B Chiral synthesis method of gamma-nitrophenol compound 浙江工业大学 2021-08-24 CN claimed
WO-2004039409-A2 COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF SWITCH BIOTECH AG (DE) 2004-05-13 WO claimed
CN-120463725-A Double-cavity tetraimidazolium cyclotomato, and preparation method and application thereof 延安大学 2025-08-12 CN disclosed
CN-115867557-A Azepine fused ring compounds and medical application thereof 中国医药研究开发中心有限公司 2023-03-28 CN disclosed
WO-2022135355-A1 METHOD FOR CATALYTICALLY ACTIVATING CARBON DIOXIDE AS CARBONYLATION REAGENT WITH INORGANIC SULFUR 内蒙古工业大学 2022-06-30 WO disclosed
US-20220162161-A1 Novel compounds and their uses as thyroid hormone receptor agonists NANJING RUIJIE PHARMA CO., LTD. (CN) 2022-05-26 US disclosed
CN-107188771-B Chiral synthesis method of gamma-nitrophenol compound 浙江工业大学 2021-08-24 CN disclosed
US-20180072997-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY 2018-03-15 US disclosed
EP-3286174-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2018-02-28 EP disclosed
WO-2016172425-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE (NO.5) LIMITED (GB) 2016-10-27 WO disclosed
US-9156822-B2 Functionally selective ligands of dopamine D2 receptors THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2015-10-13 US disclosed
US-20040147506-A1 Benzimidazolone derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-07-29 US disclosed
WO-2004039409-A2 COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF SWITCH BIOTECH AG (DE) 2004-05-13 WO disclosed
US-6699880-B1 STIMULATE MUSCARINIC ACETYLCHOLINE RECEPTORS M4, ANALGESICS BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-03-02 US disclosed
EP-1386920-A1 BENZIMIDAZOLONE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-02-04 EP disclosed
US-20030087909-A1 Fused heterocyclic inhibitors of factor Xa BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-05-08 US disclosed
EP-1221443-A1 SUBSTITUTED IMIDAZOLIDINONE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-07-10 EP disclosed
US-5763469-A Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-06-09 US disclosed
WO-1997008150-A1 SUBSTITUTED CYCLIC UREAS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-03-06 WO disclosed
US-4367337-A Process for conversion of benzimidazolones to benzotriazoles THE SHERWIN-WILLIAMS COMPANY (US) 1983-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147506-A1 Benzimidazolone derivatives HRH2, CCKAR, HRH4 HSD17B10 2757/4885HPGD 1893/4885GFER 4160/4885
US-20220162161-A1 Novel compounds and their uses as thyroid hormone receptor agonists THRA, THRB, TSHR HSD17B10 200/4885HPGD 2089/4885GFER 1960/4885
US-20180072997-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2H, POLR2E HSD17B10 1714/4885HPGD 1074/4885GFER 3895/4885
US-20030087909-A1 Fused heterocyclic inhibitors of factor Xa TFPI, F11, F12 HSD17B10 795/4885HPGD 407/4885GFER 2702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.